PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31360064-0	2019	Successful long-term treatment of non-small cell lung cancer positive for RET rearrangement with pemetrexed.	Pemetrexed	97-107	ret proto-oncogene	Homo sapiens	74-77	
31360064-3	2019	We here report a case of NSCLC positive for the CCDC6-RET fusion gene that benefited from treatment with pemetrexed over a period of 30 months, suggesting that thymidylate synthase-targeted drugs such as pemetrexed may show efficacy for NSCLC harboring RET fusions.	Pemetrexed	105-115	ret proto-oncogene	Homo sapiens	54-57	
31360064-3	2019	We here report a case of NSCLC positive for the CCDC6-RET fusion gene that benefited from treatment with pemetrexed over a period of 30 months, suggesting that thymidylate synthase-targeted drugs such as pemetrexed may show efficacy for NSCLC harboring RET fusions.	Pemetrexed	105-115	ret proto-oncogene	Homo sapiens	253-256	
31360064-3	2019	We here report a case of NSCLC positive for the CCDC6-RET fusion gene that benefited from treatment with pemetrexed over a period of 30 months, suggesting that thymidylate synthase-targeted drugs such as pemetrexed may show efficacy for NSCLC harboring RET fusions.	Pemetrexed	204-214	ret proto-oncogene	Homo sapiens	54-57	
31360064-3	2019	We here report a case of NSCLC positive for the CCDC6-RET fusion gene that benefited from treatment with pemetrexed over a period of 30 months, suggesting that thymidylate synthase-targeted drugs such as pemetrexed may show efficacy for NSCLC harboring RET fusions.	Pemetrexed	204-214	ret proto-oncogene	Homo sapiens	253-256